Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Baker

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 30, 2005
Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteinsJörg B Engel, Andrew V Schally, Gabor Halmos, et al.
ANZ Journal of Surgery|January 23, 2026
Deep Inferior Artery Perforator Flap-Enhanced Recovery After Surgery: Perspectives From Australia's Only Public Cancer-Specific HospitalRishi Kumar, Maxim Devine, Diandra Charisiou, et al.
Endocrine-Related Cancer|December 3, 2005
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteinsJörg B Engel, Andrew V Schally, Gabor Halmos, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2005
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207Gunhild Keller, Andrew V Schally, Timo Gaiser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analoguesGunhild Keller, Andrew V Schally, Timo Gaiser, et al.
Prehospital Emergency Care|January 1, 2019
Quality Assessment of Expired Naloxone Products from First-Responders' SuppliesSchuyler Pruyn, Justin Frey, Benjamin Baker, et al.
The Prostate|July 29, 2011
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteinsAnton Stangelberger, Andrew V Schally, Ferenc G Rick, et al.
Cancer Research|July 5, 2005
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogueGunhild Keller, Andrew V Schally, Timo Gaiser, et al.
Biochemical and Biophysical Research Communications|April 22, 2014
Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activityMichael J Herr, Celia M Longhurst, Benjamin Baker, et al.
Current Urology Reports|January 14, 2026
Beyond Sterility: the Urinary Microbiome in Bladder Cancer Carcinogenesis and TreatmentStephanie Aron, Margaret Meagher, Sarah Azari, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|July 30, 2005
Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteinsJörg B Engel, Andrew V Schally, Gabor Halmos, et al.
ANZ Journal of Surgery|January 23, 2026
Deep Inferior Artery Perforator Flap-Enhanced Recovery After Surgery: Perspectives From Australia's Only Public Cancer-Specific HospitalRishi Kumar, Maxim Devine, Diandra Charisiou, et al.
Endocrine-Related Cancer|December 3, 2005
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteinsJörg B Engel, Andrew V Schally, Gabor Halmos, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2005
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207Gunhild Keller, Andrew V Schally, Timo Gaiser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analoguesGunhild Keller, Andrew V Schally, Timo Gaiser, et al.
Prehospital Emergency Care|January 1, 2019
Quality Assessment of Expired Naloxone Products from First-Responders' SuppliesSchuyler Pruyn, Justin Frey, Benjamin Baker, et al.
The Prostate|July 29, 2011
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteinsAnton Stangelberger, Andrew V Schally, Ferenc G Rick, et al.
Cancer Research|July 5, 2005
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogueGunhild Keller, Andrew V Schally, Timo Gaiser, et al.
Biochemical and Biophysical Research Communications|April 22, 2014
Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activityMichael J Herr, Celia M Longhurst, Benjamin Baker, et al.
Current Urology Reports|January 14, 2026
Beyond Sterility: the Urinary Microbiome in Bladder Cancer Carcinogenesis and TreatmentStephanie Aron, Margaret Meagher, Sarah Azari, et al.
Pageof 4